The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
June 18, 2018
View Complete Issue         Table of Contents 2019 
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
June 18, 2018 (Issue: 1549)
The FDA has approved an extended-release oral suspension formulation of amphetamine (Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
Article code: 1549f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.